Search Clinical Trials | Froedtert & MCW

Keyword

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

32 results for "Cancer" and "Gynecologic Cancers" and "Lymphoma"

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL

Protocol No

JUNO-017004-TRANSCEND-CLL

Sub Category

Hematologic/Blood Related Cancers

A Phase II Study of Split-Dose R-CHOP in Older Adults with Diffuse Large B-cell Lymphoma

Split-Dose R-CHOP for Older Adults with DLBCL

Protocol No

WON-SHAH-UW18131-SPLIT-RCHOP

Sub Category

Hematologic/Blood Related Cancers

A Phase 1 Study to Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients

This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.

Protocol No

PFIZER-B7461009

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Endocrine Cancers

Breast Cancers

A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD

Protocol No

IIT-ABEDIN-NEIHULIZUMAB

Sub Category

Hematologic/Blood Related Cancers

A Phase I Study of Neihulizumab (AbGn-168H) in Patients with Steroid-refractory Acute Graft-Versus-Host Disease (sr-aGvHD)

Neihulizumab (AbGn-168H) in patients with steroid-refractory acute graft-versus-host disease

Protocol No

ABGENOMICS-2017-002-01

Sub Category

Hematologic/Blood Related Cancers

Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia

Phase 1 Study of CAR-20/19-T Cells in Pediatric and Young adult Patients with R/R B Cell ALL

Protocol No

IIT-TALANO-CART-ALL

Sub Category

Hematologic/Blood Related Cancers

A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination with Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft Versus Host Disease

Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis GVHD

Protocol No

INCYTE-INCB-39110-119-GRAVITAS

Sub Category

Hematologic/Blood Related Cancers

A Phase III, Randomized Study Of Nivolumab (OPDIVO) Plus AVD Or Brentuximab Vedotin (ADCETRIS) Plus AVD In Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Nivo plus AVD or BV plus AVD in newly diagnosed advanced HL

Protocol No

SWOG-S1826-HL

Sub Category

Hematologic/Blood Related Cancers

A randomized 3-arm Phase II study comparing 1) Bendamustine, Rituximab and high dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, high dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in patients </= 70 years old with untreated Mantle Cell Lymphoma

Comparison of BR/CR, BR/CR-A, and BR-A in patients under 70 with untreated MCL.

Protocol No

ECOG-EA4181-MCL

Sub Category

Hematologic/Blood Related Cancers

Randomized Phase II/III Study Of Venetoclax (Abt 199) Plus Chemoimmunotherapy For Myc/Bcl2 Double-Hit And Double Expressing Lymphomas

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Protocol No

ALLIANCE-A051701-DLBCL

Sub Category

Hematologic/Blood Related Cancers

Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse
Mortality after Allogeneic Transplantation in Older Adults

Composite Health Assessment Risk Model (CHARM) for Older Adults

Protocol No

CTN-1704

Sub Category

Hematologic/Blood Related Cancers

A Phase II, Open-Label, Study of Propylene Glycol-Free Melphalan HCL (EVOMELA^®) in Combination with Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

EVOMELA In Combination With Fludarabine and TBI based reduced intensity conditioning for Haplo BMT

Protocol No

IIT-HAMADANI-FLU-MEL-TBI

Sub Category

Hematologic/Blood Related Cancers

A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after Allogeneic Hematopoietic Cell Transplantation (HCT)

A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after AlloHCT

Protocol No

DF-HCC-18-265-BOS

Sub Category

Hematologic/Blood Related Cancers

Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic BMT

Protocol No

CTN-1702

Sub Category

Hematologic/Blood Related Cancers

A Phase II, Single-Arm, Open-label Study of Itacitinib, for the prevention of cytokine Release Syndrome (CRS) induced by Immune Effector Cell Therapy

A study of Itacitinib for the Prevention of CRS induced by Immune Effector Cell Therapy

Protocol No

INCYTE-INCB-39110-211-CRS

Sub Category

Hematologic/Blood Related Cancers

Phase 1, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL

YTB323 (CD19-specific CAR-T Cells) in patients with CLL/SLL and DLBCL

Protocol No

NOVARTIS-YTB323A12101

Sub Category

Hematologic/Blood Related Cancers

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Protocol No

ACCRU-SC-1601

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Eye/Orbital Cancers

Endocrine Cancers

Breast Cancers

Brain and Spine Cancers

A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

We want to find out what effects, good and/or bad, the drug combination of brentuximab vedotin and ipilimumab used together at different dose levels have on you and your relapsed or refractory Hodgkin lymphoma.

Protocol No

ECOG-E4412

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With R/R DLBCL

Protocol No

ALLIANCE-A051301-CTN1201

Sub Category

Hematologic/Blood Related Cancers

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Rituximab with or without SCT in Treating Pt with MRD-Neg MCL in First Complete Remission

Protocol No

ECOG-EA4151

Sub Category

Hematologic/Blood Related Cancers